ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.